Financhill
Sell
16

CRVO Quote, Financials, Valuation and Earnings

Last price:
$8.52
Seasonality move :
2.79%
Day range:
$7.88 - $8.85
52-week range:
$1.80 - $25.92
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
110.12x
P/B ratio:
1.89x
Volume:
462.3K
Avg. volume:
9.5M
1-year change:
-66.29%
Market cap:
$73.9M
Revenue:
--
EPS (TTM):
-$2.03

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
CRVO
CervoMed
$1.5M -$0.61 -- -52.03% $15.83
BLUE
bluebird bio
$39M -$2.42 110.17% -66.39% $6.50
CATX
Perspective Therapeutics
$123.2K -$0.31 -- -35.77% $14.39
PLX
Protalix BioTherapeutics
$23.1M -- 476.31% -- $14.50
RVP
Retractable Technologies
-- -- -- -- --
RXST
RxSight
$40.1M -$0.03 34.7% -73.88% $25.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
CRVO
CervoMed
$8.50 $15.83 $73.9M -- $0.00 0% 110.12x
BLUE
bluebird bio
$5.15 $6.50 $50.4M -- $0.00 0% 0.60x
CATX
Perspective Therapeutics
$1.95 $14.39 $144.4M -- $0.00 0% 12.62x
PLX
Protalix BioTherapeutics
$2.41 $14.50 $188.1M 80.33x $0.00 0% 3.74x
RVP
Retractable Technologies
$0.68 -- $20.4M -- $0.00 0% 0.62x
RXST
RxSight
$14.08 $25.00 $570.1M -- $0.00 0% 3.91x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
CRVO
CervoMed
-- -13.592 -- --
BLUE
bluebird bio
108.93% -0.065 70.08% 0.30x
CATX
Perspective Therapeutics
-- -2.375 -- --
PLX
Protalix BioTherapeutics
-- 1.644 -- 1.47x
RVP
Retractable Technologies
1.55% 0.051 11.72% 5.80x
RXST
RxSight
-- 1.443 -- 10.33x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
CRVO
CervoMed
-- -$7.2M -- -- -- -$8.1M
BLUE
bluebird bio
-$1.2M -$64.1M -181.94% -245.94% -519.11% -$69.2M
CATX
Perspective Therapeutics
-- -$20.9M -- -- -- -$41.2M
PLX
Protalix BioTherapeutics
$14.3M $7.2M 6.41% 8.75% 40.19% $3.6M
RVP
Retractable Technologies
-$14.8K -$5.1M -16.57% -16.83% -18.58% -$6.5M
RXST
RxSight
$28.8M -$8.6M -11.86% -11.86% -14.72% -$5.1M

CervoMed vs. Competitors

  • Which has Higher Returns CRVO or BLUE?

    bluebird bio has a net margin of -- compared to CervoMed's net margin of -573.01%. CervoMed's return on equity of -- beat bluebird bio's return on equity of -245.94%.

    Company Gross Margin Earnings Per Share Invested Capital
    CRVO
    CervoMed
    -- -$0.80 --
    BLUE
    bluebird bio
    -11.02% -$6.20 $64.8M
  • What do Analysts Say About CRVO or BLUE?

    CervoMed has a consensus price target of $15.83, signalling upside risk potential of 86.38%. On the other hand bluebird bio has an analysts' consensus of $6.50 which suggests that it could grow by 26.21%. Given that CervoMed has higher upside potential than bluebird bio, analysts believe CervoMed is more attractive than bluebird bio.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRVO
    CervoMed
    5 1 0
    BLUE
    bluebird bio
    0 5 0
  • Is CRVO or BLUE More Risky?

    CervoMed has a beta of 0.210, which suggesting that the stock is 79.037% less volatile than S&P 500. In comparison bluebird bio has a beta of 0.431, suggesting its less volatile than the S&P 500 by 56.869%.

  • Which is a Better Dividend Stock CRVO or BLUE?

    CervoMed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. bluebird bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed pays -- of its earnings as a dividend. bluebird bio pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRVO or BLUE?

    CervoMed quarterly revenues are --, which are smaller than bluebird bio quarterly revenues of $10.6M. CervoMed's net income of -$6.7M is higher than bluebird bio's net income of -$60.8M. Notably, CervoMed's price-to-earnings ratio is -- while bluebird bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed is 110.12x versus 0.60x for bluebird bio. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRVO
    CervoMed
    110.12x -- -- -$6.7M
    BLUE
    bluebird bio
    0.60x -- $10.6M -$60.8M
  • Which has Higher Returns CRVO or CATX?

    Perspective Therapeutics has a net margin of -- compared to CervoMed's net margin of --. CervoMed's return on equity of -- beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    CRVO
    CervoMed
    -- -$0.80 --
    CATX
    Perspective Therapeutics
    -- -$0.61 --
  • What do Analysts Say About CRVO or CATX?

    CervoMed has a consensus price target of $15.83, signalling upside risk potential of 86.38%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.39 which suggests that it could grow by 638.1%. Given that Perspective Therapeutics has higher upside potential than CervoMed, analysts believe Perspective Therapeutics is more attractive than CervoMed.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRVO
    CervoMed
    5 1 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is CRVO or CATX More Risky?

    CervoMed has a beta of 0.210, which suggesting that the stock is 79.037% less volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.199, suggesting its more volatile than the S&P 500 by 19.866%.

  • Which is a Better Dividend Stock CRVO or CATX?

    CervoMed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRVO or CATX?

    CervoMed quarterly revenues are --, which are smaller than Perspective Therapeutics quarterly revenues of --. CervoMed's net income of -$6.7M is higher than Perspective Therapeutics's net income of -$40.2M. Notably, CervoMed's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed is 110.12x versus 12.62x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRVO
    CervoMed
    110.12x -- -- -$6.7M
    CATX
    Perspective Therapeutics
    12.62x -- -- -$40.2M
  • Which has Higher Returns CRVO or PLX?

    Protalix BioTherapeutics has a net margin of -- compared to CervoMed's net margin of 35.65%. CervoMed's return on equity of -- beat Protalix BioTherapeutics's return on equity of 8.75%.

    Company Gross Margin Earnings Per Share Invested Capital
    CRVO
    CervoMed
    -- -$0.80 --
    PLX
    Protalix BioTherapeutics
    78.67% $0.09 $43.2M
  • What do Analysts Say About CRVO or PLX?

    CervoMed has a consensus price target of $15.83, signalling upside risk potential of 86.38%. On the other hand Protalix BioTherapeutics has an analysts' consensus of $14.50 which suggests that it could grow by 501.66%. Given that Protalix BioTherapeutics has higher upside potential than CervoMed, analysts believe Protalix BioTherapeutics is more attractive than CervoMed.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRVO
    CervoMed
    5 1 0
    PLX
    Protalix BioTherapeutics
    0 0 0
  • Is CRVO or PLX More Risky?

    CervoMed has a beta of 0.210, which suggesting that the stock is 79.037% less volatile than S&P 500. In comparison Protalix BioTherapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.351%.

  • Which is a Better Dividend Stock CRVO or PLX?

    CervoMed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix BioTherapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed pays -- of its earnings as a dividend. Protalix BioTherapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRVO or PLX?

    CervoMed quarterly revenues are --, which are smaller than Protalix BioTherapeutics quarterly revenues of $18.2M. CervoMed's net income of -$6.7M is lower than Protalix BioTherapeutics's net income of $6.5M. Notably, CervoMed's price-to-earnings ratio is -- while Protalix BioTherapeutics's PE ratio is 80.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed is 110.12x versus 3.74x for Protalix BioTherapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRVO
    CervoMed
    110.12x -- -- -$6.7M
    PLX
    Protalix BioTherapeutics
    3.74x 80.33x $18.2M $6.5M
  • Which has Higher Returns CRVO or RVP?

    Retractable Technologies has a net margin of -- compared to CervoMed's net margin of -18.58%. CervoMed's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

    Company Gross Margin Earnings Per Share Invested Capital
    CRVO
    CervoMed
    -- -$0.80 --
    RVP
    Retractable Technologies
    -0.14% -$0.07 $84.8M
  • What do Analysts Say About CRVO or RVP?

    CervoMed has a consensus price target of $15.83, signalling upside risk potential of 86.38%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that CervoMed has higher upside potential than Retractable Technologies, analysts believe CervoMed is more attractive than Retractable Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRVO
    CervoMed
    5 1 0
    RVP
    Retractable Technologies
    0 0 0
  • Is CRVO or RVP More Risky?

    CervoMed has a beta of 0.210, which suggesting that the stock is 79.037% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

  • Which is a Better Dividend Stock CRVO or RVP?

    CervoMed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

  • Which has Better Financial Ratios CRVO or RVP?

    CervoMed quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. CervoMed's net income of -$6.7M is lower than Retractable Technologies's net income of -$1.9M. Notably, CervoMed's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed is 110.12x versus 0.62x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRVO
    CervoMed
    110.12x -- -- -$6.7M
    RVP
    Retractable Technologies
    0.62x -- $10.3M -$1.9M
  • Which has Higher Returns CRVO or RXST?

    RxSight has a net margin of -- compared to CervoMed's net margin of -14.77%. CervoMed's return on equity of -- beat RxSight's return on equity of -11.86%.

    Company Gross Margin Earnings Per Share Invested Capital
    CRVO
    CervoMed
    -- -$0.80 --
    RXST
    RxSight
    71.59% -$0.15 $281.2M
  • What do Analysts Say About CRVO or RXST?

    CervoMed has a consensus price target of $15.83, signalling upside risk potential of 86.38%. On the other hand RxSight has an analysts' consensus of $25.00 which suggests that it could grow by 77.56%. Given that CervoMed has higher upside potential than RxSight, analysts believe CervoMed is more attractive than RxSight.

    Company Buy Ratings Hold Ratings Sell Ratings
    CRVO
    CervoMed
    5 1 0
    RXST
    RxSight
    3 3 0
  • Is CRVO or RXST More Risky?

    CervoMed has a beta of 0.210, which suggesting that the stock is 79.037% less volatile than S&P 500. In comparison RxSight has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock CRVO or RXST?

    CervoMed has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. RxSight offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CervoMed pays -- of its earnings as a dividend. RxSight pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios CRVO or RXST?

    CervoMed quarterly revenues are --, which are smaller than RxSight quarterly revenues of $40.2M. CervoMed's net income of -$6.7M is lower than RxSight's net income of -$5.9M. Notably, CervoMed's price-to-earnings ratio is -- while RxSight's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CervoMed is 110.12x versus 3.91x for RxSight. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    CRVO
    CervoMed
    110.12x -- -- -$6.7M
    RXST
    RxSight
    3.91x -- $40.2M -$5.9M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will NVIDIA Return to Its 52-Week High?
Will NVIDIA Return to Its 52-Week High?

NVIDIA (NASDAQ:NVDA) has been among the best-performing investments of the…

Will JP Morgan’s AI Advisor Be a Winner?
Will JP Morgan’s AI Advisor Be a Winner?

JPMorgan Chase is rolling out “JPM WealthAI for high-net-worth clients.…

Is Revolve Group Stock a Buy, Sell or Hold?
Is Revolve Group Stock a Buy, Sell or Hold?

Recently, Revolve Group (NYSE:RVLV) management delivered some fairly positive business…

Stock Ideas

Sell
45
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Buy
53
Is MSFT Stock a Buy?

Market Cap: $2.9T
P/E Ratio: 33x

Sell
50
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 38x

Alerts

Buy
52
RGC alert for Apr 12

Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.

Buy
52
SLP alert for Apr 12

Simulations Plus [SLP] is up 26.73% over the past day.

Buy
89
GDXU alert for Apr 12

MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock